Objective The hypothesis that been set forward that use of Renin Angiotensin Aldosterone
System (RAAS) inhibitors is associated with COVID− 19 severity. We set-up a multicenter …

Introduction The epidemic due to severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infection has been spreading globally, raising increasing concerns. There are …

To investigate the effects of renin‐angiotensin‐aldosterone system (RAAS) inhibitors on the
prognosis in patients with coronavirus disease 2019 (COVID‐19). A meta‐analysis was …

Among the multiple uncertainties surrounding the novel coronavirus disease (COVID-19)
pandemic, a research letter published in The Lancet implicated drugs that antagonize the …

Background and aims: Coronavirus disease 2019 (COVID-19) has been observed to cause
a high mortality in people with cardiometabolic diseases. Renin–angiotensin–aldosterone …

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has recently reached the pandemic level. 1 COVID-19 is …

Background Reports on the effects of renin–angiotensin–aldosterone system (RAAS)
inhibitors on the clinical outcomes of coronavirus disease-19 (COVID-19) have been …

Introduction The safety of renin–angiotensin–aldosterone system inhibitors (RAASi) among
COVID-19 patients has been controversial since the onset of the pandemic. Methods Digital …

Importance The chronic receipt of angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs) has been assumed to exacerbate complications …

Background and rationale Some studies of hospitalized patients suggested that the risk of
death and/or severe illness due to COVID-19 is not associated with the use of angiotensin …